Akeso (9926 HK): Synthetic Expert Call Transcript (14 Oct 2026)
Ivonescimab’s head-to-head overall survival (OS) victory over Keytruda in HARMONi-2 (median OS 30.8 months vs 22.6 months, HR 0.73) validates the...
5 Views
Aequitas: Akeso Inc Placement Past Deals Have Been Weak but Current Raise Is Less Opportunistic
Akeso is looking to raise around US$250m in a primary offering. In this note, we talk about the deal dynamics and run the deal through our ECM...
68 Views
Akeso (9926 HK) - Eyes on Harmoni-3 Readout in 2H26
Akeso reported product sales of RMB1.8bn in 1H26, equivalent to 37% of our previous FY26 forecast, below our expectations despite broader NRDL...
89 Views
Akeso 9926.HK: 1H26 Results Missed on Topline; Upcoming Events on Harmoni-3 Readout and FDA PDUFA
Akeso 1H26 missed on topline. See inside for our thought on Akeso share price underperformance, upcoming catalysts on ivonescimab, 1H26 results...
109 Views
Quam Morning Note (28 Aug) - Akeso
The company currently has a portfolio of over 50 innovative programs covering the therapeutic areas of oncology, autoimmune and metabolic...
95 Views